Published in BMC Dermatol on January 28, 2008
Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal (2009) 2.11
Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease. PLoS One (2011) 1.48
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models. BMC Pharmacol (2009) 1.20
Genetic disruption of Pten in a novel mouse model of tomaculous neuropathy. EMBO Mol Med (2012) 1.17
Participation of mammalian target of rapamycin complex 1 in Toll-like receptor 2- and 4-induced neutrophil activation and acute lung injury. Am J Respir Cell Mol Biol (2009) 1.16
Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors. J Transl Med (2010) 1.15
Targeted treatments for cognitive and neurodevelopmental disorders in tuberous sclerosis complex. Neurotherapeutics (2010) 1.08
Genetics and molecular biology of tuberous sclerosis complex. Curr Genomics (2008) 1.08
Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex. J Child Neurol (2008) 1.02
Emerging pharmacotherapies for neurodevelopmental disorders. J Dev Behav Pediatr (2010) 0.99
Rapamycin has a beneficial effect on controlling epilepsy in children with tuberous sclerosis complex: results of 7 children from a cohort of 86. Childs Nerv Syst (2013) 0.88
Hereditary genodermatoses with cancer predisposition. Hematol Oncol Clin North Am (2010) 0.83
Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex. Neuro Oncol (2015) 0.80
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 24.19
The tuberous sclerosis complex. N Engl J Med (2006) 13.53
Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med (2005) 7.83
Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell (1993) 7.59
Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet (2005) 7.15
Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science (1997) 6.10
Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat Cell Biol (2002) 5.37
Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell (2001) 4.98
Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol (2006) 4.24
Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet (2000) 3.44
Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype--phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex. Eur J Hum Genet (2005) 3.43
Tuberous sclerosis complex: advances in diagnosis, genetics, and management. J Am Acad Dermatol (2007) 3.29
Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Respir Crit Care Med (2001) 2.94
Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res (2002) 2.81
Molecular genetic advances in tuberous sclerosis. Hum Genet (2000) 2.72
Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am J Hum Genet (1996) 2.67
Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nat Biotechnol (2001) 2.59
Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Genes Chromosomes Cancer (2005) 2.42
Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. Genet Med (2007) 2.20
Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet (2003) 2.09
Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatr Res (2004) 2.09
Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol (2006) 1.73
Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex. Am J Kidney Dis (2006) 1.73
Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors. Am J Pathol (1997) 1.63
Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J Neuropathol Exp Neurol (2004) 1.52
Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant (2004) 1.50
Dramatic effect of sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis complex. Eur J Intern Med (2007) 1.43
Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation (2004) 1.40
Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation (2004) 1.39
Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs (2006) 1.25
Combination of a rapamycin analog (CCI-779) and interferon-gamma is more effective than single agents in treating a mouse model of tuberous sclerosis complex. Genes Chromosomes Cancer (2006) 1.06
Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial. Br J Dermatol (2005) 0.96
TSC1-2 tumour suppressor and regulation of mTOR signalling: linking cell growth and proliferation? Curr Opin Genet Dev (2005) 0.96
Carbon dioxide and pulsed dye laser treatment of angiofibromas in 29 patients with tuberous sclerosis. Br J Dermatol (2002) 0.95
Complete inactivation of the TSC2 gene leads to formation of hamartomas. Am J Hum Genet (1999) 0.95
Cilomilast, tacrolimus and rapamycin modulate dendritic cell function in the elicitation phase of allergic contact dermatitis. Br J Dermatol (2005) 0.87
Loss of expression of tuberin and hamartin in tuberous sclerosis complex-associated but not in sporadic angiofibromas. J Cutan Pathol (2003) 0.85
Reduction of expression of tuberin, the tuberous-sclerosis-complex-gene-2 product in tuberous sclerosis complex associated connective tissue nevi and sporadic squamous and basal cell carcinomas. J Cutan Pathol (2002) 0.82
Treatment of angiofibromas with a scanning carbon dioxide laser: a clinicopathologic study with long-term follow-up. J Am Acad Dermatol (2001) 0.82
Hamartomas and tubers from defects in hamartin-tuberin. J Am Acad Dermatol (2004) 0.81
The "bumps" on my face. J Am Acad Dermatol (2004) 0.80
Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med (2004) 9.55
CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC,RTOG consensus guidelines. Radiother Oncol (2003) 3.78
PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest (2007) 3.54
Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Genes Chromosomes Cancer (2005) 2.42
The role of pretreatment percutaneous endoscopic gastrostomy in facilitating therapy of head and neck cancer and optimizing the body mass index of the obese patient. JPEN J Parenter Enteral Nutr (2009) 2.16
Intensity-modulated radiation therapy for head and neck carcinoma. Oncologist (2007) 1.94
Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin Infect Dis (2001) 1.79
Postoperative complications of salvage total laryngectomy. Cancer (2005) 1.53
Patterns of coordinated anatomical change in human cortical development: a longitudinal neuroimaging study of maturational coupling. Neuron (2011) 1.52
Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys (2010) 1.52
Programmed cell death in trypanosomatids and other unicellular organisms. Int J Parasitol (2003) 1.50
Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease. PLoS One (2011) 1.48
Correlation of screening and confirmatory results in tiered immunogenicity testing by solution-phase bridging assays. J Pharm Biomed Anal (2012) 1.43
Intestinal macrophage/epithelial cell-derived CCL11/eotaxin-1 mediates eosinophil recruitment and function in pediatric ulcerative colitis. J Immunol (2008) 1.33
PET monitoring of therapy response in head and neck squamous cell carcinoma. J Nucl Med (2009) 1.31
Acupuncture for pain and dysfunction after neck dissection: results of a randomized controlled trial. J Clin Oncol (2010) 1.27
Hypofractionated dose-painting intensity modulated radiation therapy with chemotherapy for nasopharyngeal carcinoma: a prospective trial. Int J Radiat Oncol Biol Phys (2010) 1.25
Results of surgical salvage after failure of definitive radiation therapy for early-stage squamous cell carcinoma of the glottic larynx. Arch Otolaryngol Head Neck Surg (2006) 1.25
The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography. Int J Radiat Oncol Biol Phys (2008) 1.22
Head-and-neck target delineation among radiation oncology residents after a teaching intervention: a prospective, blinded pilot study. Int J Radiat Oncol Biol Phys (2008) 1.21
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models. BMC Pharmacol (2009) 1.20
Racial/ethnic differences in CD4 T cell count and viral load at presentation for medical care and in follow-up after HIV-1 infection. AIDS (2002) 1.19
Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation. Cancer Res (2009) 1.19
The S1P2 sphingosine 1-phosphate receptor is essential for auditory and vestibular function. Hear Res (2006) 1.15
Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors. J Transl Med (2010) 1.15
Prognostic factors of recurrence in salivary carcinoma ex pleomorphic adenoma, with emphasis on the carcinoma histologic subtype: a clinicopathologic study of 43 cases. Hum Pathol (2010) 1.14
Mating factor linkage and genome evolution in basidiomycetous pathogens of cereals. Fungal Genet Biol (2006) 1.13
Oral cavity and oropharynx tumors. Radiol Clin North Am (2007) 1.12
Differences in the corneal biomechanical effects of surface ablation compared with laser in situ keratomileusis using a microkeratome or femtosecond laser. J Cataract Refract Surg (2008) 1.11
Current and emerging treatment options for nasopharyngeal carcinoma. Onco Targets Ther (2012) 1.10
Corneal biomechanical measurements before and after laser in situ keratomileusis. J Cataract Refract Surg (2008) 1.07
Adenoid cystic carcinoma of the major salivary glands treated with surgery and radiation. Laryngoscope (2005) 1.07
Combination of a rapamycin analog (CCI-779) and interferon-gamma is more effective than single agents in treating a mouse model of tuberous sclerosis complex. Genes Chromosomes Cancer (2006) 1.06
Geometric factors influencing dosimetric sparing of the parotid glands using IMRT. Int J Radiat Oncol Biol Phys (2006) 1.04
RNA-mediated inhibition of HIV in a gene therapy setting. Ann N Y Acad Sci (2003) 1.03
An investigation of intensity-modulated radiation therapy versus conventional two-dimensional and 3D-conformal radiation therapy for early stage larynx cancer. Radiat Oncol (2010) 0.99
Corneal biomechanical properties in normal, forme fruste keratoconus, and manifest keratoconus after statistical correction for potentially confounding factors. Cornea (2011) 0.97
Average arterial input function for quantitative dynamic contrast enhanced magnetic resonance imaging of neck nodal metastases. BMC Med Phys (2009) 0.97
Method to account for dose fractionation in analysis of IMRT plans: modified equivalent uniform dose. Int J Radiat Oncol Biol Phys (2005) 0.95
Severe radiation dermatitis in patients with locally advanced head and neck cancer treated with concurrent radiation and cetuximab. Am J Clin Oncol (2009) 0.94
Radiation impairs perineural invasion by modulating the nerve microenvironment. PLoS One (2012) 0.94
Predictors of outcome for advanced-stage supraglottic laryngeal cancer. Head Neck (2009) 0.94
Patterns and incidence of neural invasion in patients with cancers of the paranasal sinuses. Arch Otolaryngol Head Neck Surg (2009) 0.93
A population-based atlas and clinical target volume for the head-and-neck lymph nodes. Int J Radiat Oncol Biol Phys (2004) 0.93
Comparison of treatment plans using intensity-modulated radiotherapy and three-dimensional conformal radiotherapy for paranasal sinus carcinoma. Int J Radiat Oncol Biol Phys (2003) 0.93
Target volume delineation in oropharyngeal cancer: impact of PET, MRI, and physical examination. Int J Radiat Oncol Biol Phys (2011) 0.93
Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779. BMC Pharmacol (2007) 0.93
Reirradiation of locally recurrent nasopharynx cancer with external beam radiotherapy with or without brachytherapy. Int J Radiat Oncol Biol Phys (2010) 0.93
Prevalence of intracardiac shunting in children with sickle cell disease and stroke. J Pediatr (2009) 0.92
Concurrent Chemoradiotherapy With Cisplatin Versus Cetuximab for Squamous Cell Carcinoma of the Head and Neck. Am J Clin Oncol (2016) 0.91
Genetically modified live attenuated parasites as vaccines for leishmaniasis. Indian J Med Res (2006) 0.91
Temporal gene expression patterns in G93A/SOD1 mouse. Amyotroph Lateral Scler Other Motor Neuron Disord (2004) 0.90
Comparing primary tumors and metastatic nodes in head and neck cancer using intravoxel incoherent motion imaging: a preliminary experience. J Comput Assist Tomogr (2013) 0.90
Definitive treatment of metastatic nasopharyngeal carcinoma: Report of 5 cases with review of literature. Head Neck (2010) 0.89
Postoperative intensity-modulated radiation therapy for cancers of the paranasal sinuses, nasal cavity, and lacrimal glands: technique, early outcomes, and toxicity. Head Neck (2008) 0.88
Expression of calreticulin P-domain results in impairment of secretory pathway in Leishmania donovani and reduced parasite survival in macrophages. Int J Parasitol (2002) 0.88
Tissue microarray evidence of association between p16 and phosphorylated eIF4E in tonsillar squamous cell carcinoma. Head Neck (2010) 0.87
Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients. J Support Oncol (2006) 0.87
External beam radiation therapy for locally advanced and metastatic gastrointestinal stromal tumors. Radiat Oncol (2013) 0.86
A web based resource characterizing the zebrafish developmental profile of over 16,000 transcripts. Gene Expr Patterns (2007) 0.86
Should cetuximab replace Cisplatin for definitive chemoradiotherapy in locally advanced head and neck cancer? J Clin Oncol (2012) 0.85
An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma. Clin Cancer Res (2013) 0.85
An atypical protein disulfide isomerase from the protozoan parasite Leishmania containing a single thioredoxin-like domain. J Biol Chem (2002) 0.84
High-dose-rate interstitial brachytherapy in recurrent and previously irradiated head and neck cancers--preliminary results. Brachytherapy (2007) 0.84
Viable tumor in postchemoradiation neck dissection specimens as an indicator of poor outcome. Head Neck (2010) 0.83
Advances in nasopharyngeal carcinoma. Curr Opin Oncol (2005) 0.83
Marginal recurrences after selective targeting with intensity-modulated radiotherapy for oral tongue cancer. Head Neck (2011) 0.82
Intensity-modulated radiation therapy in head and neck cancers: dosimetric advantages and update of clinical results. Am J Clin Oncol (2005) 0.81
SNP identification, haplotype analysis, and parental origin of mutations in TSC2. Hum Genet (2002) 0.81
Phase III quality-of-life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer--RTOG 97-09. Int J Radiat Oncol Biol Phys (2003) 0.81
A study of planning dose constraints for treatment of nasopharyngeal carcinoma using a commercial inverse treatment planning system. Int J Radiat Oncol Biol Phys (2004) 0.81
Similar trends in serum VEGF-D levels and kidney angiomyolipoma responses with longer duration sirolimus treatment in adults with tuberous sclerosis. PLoS One (2013) 0.81
Zebrafish fat-free, a novel Arf effector, regulates phospholipase D to mediate lipid and glucose metabolism. Biochim Biophys Acta (2010) 0.81
Student and faculty observations and perceptions of professionalism in online domain scenarios. Am J Pharm Educ (2013) 0.80
An electrochemiluminescence (ECL)-based assay for the specific detection of anti-drug antibodies of the IgE isotype. J Pharm Biomed Anal (2013) 0.80
Ensuring transparency and minimization of methodologic bias in preclinical pain research: PPRECISE considerations. Pain (2016) 0.80
Migration from full-head mask to "open-face" mask for immobilization of patients with head and neck cancer. J Appl Clin Med Phys (2013) 0.79
Accurate positioning for head and neck cancer patients using 2D and 3D image guidance. J Appl Clin Med Phys (2010) 0.79
High-dose-rate intraoperative radiation therapy for recurrent head-and-neck cancer. Int J Radiat Oncol Biol Phys (2009) 0.79
Selective radiotherapy for the treatment of head and neck Merkel cell carcinoma. Cancer (2011) 0.78
Simplifying intensity-modulated radiotherapy plans with fewer beam angles for the treatment of oropharyngeal carcinoma. J Appl Clin Med Phys (2007) 0.78
A treatment planning analysis of inverse-planned and forward-planned intensity-modulated radiation therapy in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys (2007) 0.78
Management of cervical metastases in advanced squamous cell carcinoma of the base of tongue. Arch Otolaryngol Head Neck Surg (2003) 0.77
Ocular surface reconstruction with keratolimbal allograft for the treatment of severe or recurrent symblepharon. Cornea (2015) 0.77
The effect of significant tumor reduction on the dose distribution in intensity modulated radiation therapy for head-and-neck cancer: a case study. Med Dosim (2008) 0.76
Radiation therapy in the management of Merkel cell carcinoma: current perspectives. Expert Rev Dermatol (2011) 0.75
Melanoma metastatic to multiple visceral organs: further considerations. Oncology (Williston Park) (2010) 0.75
Secondary skull base malignancies in survivors of retinoblastoma: the memorial sloan kettering cancer center experience. Skull Base (2011) 0.75
A unique complication associated with concurrent chemoradiation for the treatment of locally advanced head and neck cancer. Clin Med Oncol (2008) 0.75
We are pleased to present you with this Special Issue of the Journal of Women's Health highlighting the main topics covered at the meeting. Introduction. J Womens Health (Larchmt) (2014) 0.75
Introduction: Head and neck cancer. Semin Radiat Oncol (2012) 0.75
Feasibility of reirradiation of recurrent sinonasal carcinoma in the periorbital region using hypofractionated image-guided intensity-modulated radiation therapy. Head Neck (2010) 0.75